Purpose: To evaluate the duration of effect of rHuPH20 on SC absorption of cetuximab and to develop a mechanistic pharmacokinetic model linking the kinetics of rHuPH20 action with hyaluronan (HA) homeostasis and absorption of cetuximab from the SC space.
Methods: Serum pharmacokinetics of cetuximab was evaluated after IV and SC dosing at 0.4 and 10 mg/kg (control groups). In test groups, SC cetuximab was administered simultaneously with rHuPH20 (Co-Injection) or 12 h after injection of rHuPH20 (Pre-Injection). Mechanistic pharmacokinetic model was developed to simultaneously capture cetuximab kinetics in all groups.
Results: Administration of rHuPH20 resulted in a faster absorption of cetuximab; the difference between co-injection and pre-injection groups appeared to be dependent on the dose level. The model combined three major components: kinetics of rHuPH20 at SC site; HA homeostasis and its disruption by rHuPH20; and cetuximab systemic disposition and the effect of HA disruption on cetuximab SC absorption. The model provided good description of experimental data obtained in this study and collected previously.
Conclusions: Proposed model can serve as a potential translational framework for capturing the effect of rHuPH20 across multiple preclinical species and in human studies and can be used for optimization of SC delivery of biotherapeutics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11095-022-03294-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systematic comparison of fluorescence imaging in the near-infrared and shortwave-infrared spectral range using clinical tumor samples containing cetuximab-IRDye800CW.
J Biomed Opt
January 2025
University Medical Centre Groningen, Department of Nuclear Medicine and Molecular Imaging, Groningen, The Netherlands.
Article Synopsis
- Shortwave-infrared (SWIR) imaging is suggested to improve contrast in fluorescence-guided surgery compared to near-infrared (NIR) imaging, but it has only been tested in animal studies so far.
- The study aims to evaluate the benefits of SWIR imaging in clinical samples treated with the NIR dye cetuximab-IRDye800CW, focusing on tumor-targeted applications in penile and head and neck cancers.
- Results indicate that while SWIR performs similarly to NIR in penile cancer samples, NIR outperforms SWIR in most criteria for head and neck cancer due to high background autofluorescence, suggesting that SWIR may enhance contrast in some situations but not universally across all clinical
Antibody-Conjugated Polymersomes with Encapsulated Indocyanine Green J-Aggregates and High Near-Infrared Absorption for Molecular Photoacoustic Cancer Imaging.
ACS Appl Mater Interfaces
February 2024
McKetta Department of Chemical Engineering, The University of Texas at Austin, Austin, Texas 78712, United States.
Article Synopsis
- Imaging is essential in cancer care for detection, diagnosis, and monitoring, with photoacoustic imaging (PAI) gaining attention due to its high sensitivity and tissue penetration.
- A novel approach involves encapsulating indocyanine green J (ICGJ) in biodegradable polymersomes to enhance PAI, achieving a small hydrodynamic diameter for better in vivo applications and targeted delivery through conjugation with EGFR-targeting antibodies.
- The polymersome-labeled breast cancer cells can be detected via PAI, even in turbid conditions, demonstrating the method's potential for clinical applications like tumor margin detection and lymph node evaluation.
A phase I, single-center, open-label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [ C] encorafenib in healthy male subjects.
Pharmacol Res Perspect
October 2023
Pfizer Inc. Worldwide Research, Development and Medical, Boulder, Colorado, USA.
Encorafenib is a novel kinase inhibitor of BRAF V600E as well as wild-type BRAF and CRAF and has received approval, in combination with binimetinib, to treat BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma or in combination with cetuximab to treat BRAF V600E mutation-positive colorectal cancer. The absorption, distribution, metabolism and excretion (ADME) of encorafenib was studied by administering [ C] encorafenib (100 mg containing 90 μCi of radiolabeled material) to 4 healthy male subjects (NCT01436656). Following a single oral 100-mg dose of [ C] encorafenib to healthy male subjects, the overall recovery of radioactivity in the excreta was ≥93.
View Article and Find Full Text PDFA Novel Near-IR Absorbing Ruthenium(II) Complex as Photosensitizer for Photodynamic Therapy and its Cetuximab Bioconjugates.
Chembiochem
August 2023
Chimie ParisTech, PSL University, CNRS, Institute of Chemistry for Life and Health Sciences, Laboratory for Inorganic Chemical Biology, 75005, Paris, France.
A novel Ru(II) cyclometalated photosensitizer (PS), Ru-NH , for photodynamic therapy (PDT) of formula [Ru(appy)(bphen) ]PF (where appy=4-amino-2-phenylpyridine and bphen=bathophenanthroline) and its cetuximab (CTX) bioconjugates, Ru-Mal-CTX and Ru-BAA-CTX (where Mal=maleimide and BAA=benzoylacrylic acid) were synthesised and characterised. The photophysical properties of Ru-NH revealed absorption maxima around 580 nm with an absorption up to 725 nm. The generation of singlet oxygen ( O ) upon light irradiation was confirmed with a O quantum yield of 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!